Behavioral symptoms in dementia: theories and therapies. International conferencePATTERSON, Marian B.Alzheimer disease and associated disorders. 1994, Vol 8, issn 0893-0341, 162 p., SUP3Conference Proceedings

Neuroanatomical targets of neuroleptic drugs as revealed by fos immunochemistryFIBIGER, H. C.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 33-36, issn 0160-6689, SUPBConference Paper

Preferential activation of cortical dopamine neurotransmission by clozapine : functional significanceMOGHADDAM, B.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 27-29, issn 0160-6689, SUPBConference Paper

Seizures during clozapine therapyDEVINSKY, O; PACIA, S. V.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 153-156, issn 0160-6689, SUPBConference Paper

Clozapine and noradrenergic function : support for a novel hypothesis for superior efficacyBREIER, A.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 122-125, issn 0160-6689, SUPBConference Paper

Clozapine : 1994. SymposiumKANE, John M; MELTZER, Herbert Y; LIEBERMAN, Jeffrey A et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, issn 0160-6689, SUPBConference Proceedings

G-CSF and the management of clozapine-induced agranulocytosisGERSON, S. L.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 139-142, issn 0160-6689, SUPBConference Paper

Motor and mental side effects of clozapineGERLACH, J; PEACOCK, L.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 107-109, issn 0160-6689, SUPBConference Paper

Symposium commemorating the 50th anniversary of the experimental production of renal hypertension by Harry Goldblatt: proceedings/Renal origin of hypertension: progress over 50 years, symposium, Toledo OH, October 1984GOLDBLATT, P. J; GOLDBLATT, D; HOPPS, H. C et al.Journal of hypertension. 1986, Vol 4, issn 0263-6352, 109 p., suppl. 4Conference Proceedings

Identification of the neural systems subserving the actions of clozapine : clues from immediate-early gene expressionDEUTCH, A. Y.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 37-42, issn 0160-6689, SUPBConference Paper

Predictors of clozapine response in schizophreniaPICKAR, D; OWEN, R. R; LITMAN, R. E et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 129-132, issn 0160-6689, SUPBConference Paper

Clozapine in treatment-refractory mood disordersKIMMEL, S. E; CALABRESE, J. R; WOYSHVILLE, M. J et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 91-93, issn 0160-6689, SUPBConference Paper

Clozapine, negative symptoms, and extrapyramidal side effectsKANE, J. M; SAFFERMAN, A. Z; POLLACK, S et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 74-77, issn 0160-6689, SUPBConference Paper

The effects of clozapine on neurocognition : an overviewGOLDBERG, T. E; WEINBERGER, D. R.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 88-90, issn 0160-6689, SUPBConference Paper

Limbic-prefrontal connectivity and clozapineKNABLE, M. B; WEINBERGER, D. R.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 70-73, issn 0160-6689, SUPBConference Paper

Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptorsKERWIN, R. W; PILOWSKY, L; MUNRO, J et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 57-62, issn 0160-6689, SUPBConference Paper

Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicityOLNEY, J. W; FARBER, N. B.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 43-46, issn 0160-6689, SUPBConference Paper

The role of 5-HT₃-like receptors in the action of clozapineWANG, R. Y; ASHBY, C. R; EDWARDS, E et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 23-26, issn 0160-6689, SUPBConference Paper

Brain region effects of clozapine on amino acid and monoamine transmissionYAMAMOTO, B. K; PEHEK, E. A; MELTZER, H. Y et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 8-14, issn 0160-6689, SUPBConference Paper

Effects of clozapine on cognitive function in schizophreniaLEE, M. A; THOMPSON, P. A; MELTZER, H. Y et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 82-87, issn 0160-6689, SUPBConference Paper

The pharmacoeconomics of clozapine : a reviewMELTZER, H. Y; COLA, P. A.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 161-165, issn 0160-6689, SUPBConference Paper

Substance abuse and clozapine treatmentBUCKLEY, P; THOMPSON, P. A; WAY, L et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 114-116, issn 0160-6689, SUPBConference Paper

Clozapine dose in the United States and Europe : implications for therapeutic and adverse effectsFLEISCHHACKER, W. W; HUMMER, M; KURZ, M et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 78-81, issn 0160-6689, SUPBConference Paper

Cerebral morphometry and clozapine treatment in schizophreniaBILDER, R. M; HOUWEI HU; CHAKOS, M. H et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 53-56, issn 0160-6689, SUPBConference Paper

Predictors of response to clozapineLIEBERMAN, J. A; KANE, J. M; SAFFERMAN, A. Z et al.The Journal of clinical psychiatry. 1994, Vol 55, Num SEP, pp 126-128, issn 0160-6689, SUPBConference Paper